Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Recruiting · NCT05833217 · Interventional (participants receive a specific treatment) · Lead sponsor: Stanford University
View the official record on ClinicalTrials.gov →Interventions studied
Adipose Tissue BiopsySteady State Plasma Glucose (SSPG) Test
What this trial is about
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Ages 18 to 80
- BMI ≥ 25 kg/m2
- not currently pregnant
Exclusion criteria
- Arm 2 (Adipose Tissue Biopsy) exclusions include
- pregnancy
- prior liposuction
- recent change in weight (\> 2 kg in one month)
- bleeding disorders
- anticoagulant use
- Arm 3 (healthy controls only) exclusions include patients with
- major organ disease
- diabetes
- history of liposuction
- bariatric surgery
- eating disorders
- psychiatric disorders
- pregnancy or lactation
- recent change in weight (over the past 12 weeks),
- use of weight loss medication or oral steroids
- hematocrit \< 33%
- fasting glucose \>= 126 mg/dL
- blood pressure \>160/100 mmHg
Where it is running
2 locations listed across 1 US state.
- Clinical and Translational Research Unit - Palo Alto, California, United States
- Stanford Health - Palo Alto, California, United States